RI Research Instruments Awarded $7.7M Linear Accelerator Contract from DoE Brookhaven National Laboratory
News Apr 23, 2010
RI Research Instruments GmbH, a majority-owned subsidiary of Bruker Energy & Supercon Technologies (BEST), Inc., has announced the award of a $7.7 million contract from the U.S. Department of Energy's Brookhaven National Laboratory. The contract is for the turn-key supply of a 200 MeV electron injection linear accelerator for BNL's next-generation National Synchrotron Light Source (NSLS-II).
This new contract covers the engineering, manufacturing, integration, delivery, installation and commissioning of the linear accelerator (linac). Delivery is expected in January 2012. A linac represents the first key element of third generation synchrotron light sources. It generates, accelerates and delivers an electron beam of superior quality to be used in a storage ring for generating x-rays, ultraviolet light and infrared light for research in such diverse fields as biology and medicine, chemistry and environmental sciences, physics, and materials science.
According to a BNL publication, their current light source - the National Synchrotron Light Source (NSLS). Meeting the critical scientific challenges of the United States energy future will require advanced new capabilities that a new facility called NSLS-II is expected to provide. Construction of the NSLS-II began in 2009 and initial operation is expected in 2015.
NSLS-II will be a new medium-energy electron storage ring (3 billion electron-volts) designed to deliver intensity and brightness, and produce x-rays more than 10,000 times brighter than the current NSLS.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE